Champions Oncology Inc reports results for the quarter ended April 30 - Earnings Summary
24/07/2025 17:56
Champions Oncology Inc CSBR.OQ reported a quarterly adjusted loss of 7 cents per share for the quarter ended April 30, lower than the same quarter last year, when the company reported EPS of 1 cents. The lone analyst forecast for the quarter was for a loss of 20 cents per share. Revenue fell 11.8% to $12.36 million from a year ago; analysts expected $12.01 million. Champions Oncology Inc's reported EPS for the quarter was a loss of 13 cents. The company reported a quarterly loss of $1.83 million. Champions Oncology Inc shares had risen by 5.2% this quarter and lost 9.6% so far this year. FORECAST CHANGES The mean earnings estimate of analysts was unchanged in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Champions Oncology Inc is $12.00, about 35.4% above its last closing price of $7.75 This summary was machine generated from LSEG data July 24 at 04:56 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Apr. 30 2025 | -0.20 | -0.07 | Beat |
| Jan. 31 2025 | -0.01 | 0.36 | Beat |
| Oct. 31 2024 | 0.01 | 0.05 | Beat |
| Jul. 31 2024 | -0.03 | 0.11 | Beat |